This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Exploring the potential of INBX-101, a recombinant AAT Fc-fusion protein, in treating patients with AATD
Ticker(s): INBXWho's the expert?
Institution: UCLA
- Assistant Professor & Medical Director, Liver Transplant Intensive Care Unit ,Medical Director, COPD Program UCLA Division of Pulmonary and Critical Care Medicine.
- Treats over 100 Alpha-1 patients and runs alpha-1 CRC clinic.
- Has been a PI on multiple AATD trials; as a Medical Director of COPD Program at the David Geffen School of Medicine at UCLA, focuses and leads clinical and research projects in COPD, alpha-1 antitrypsin deficiency syndrome and lung nodule/lung cancer.
Interview GoalTo better understand the potential of a recombinant AAT Fc-fusion protein in treating patients AAT over plasma derived options after Phase 1 results.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
